Concepedia

Marco Basiricò

MB

12

Publications

454

Citations

11

H-Index

2013

Active since

Affiliations

Candiolo Cancer Institute(Current)

University of Turin

Istituti di Ricovero e Cura a Carattere Scientifico

Fondazione Edo ed Elvo Tempia

Istituto Ortopedico Rizzoli

Marco Basiricò is an author at Candiolo Cancer Institute specializing in tumor biology, cell biology, and cancer research.

ORCID

Top concepts

Publications per year

2013–2022

12

Publications

12

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

Ymera Pignochino, Carmine Dell’Aglio, Marco Basiricò et al. · Clinical Cancer Research · 2013 · 107 citations

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio et al. · Molecular Cancer · 2017 · 69 citations · Full text

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody

Martina Sanlorenzo, Igor Vujic, Arianna Floris et al. · Clinical Cancer Research · 2018 · 53 citations · Full text

CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes

Valeria Leuci, Chiara Donini, Giovanni Grignani et al. · Clinical Cancer Research · 2020 · 38 citations · Full text

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

Ymera Pignochino, Carmine Dell’Aglio, Simona Inghilleri et al. · BMC Cancer · 2015 · 34 citations · Full text

Rows per page

1–5 of 12